CORGARD

LOE ApproachingSM

nadolol

NDAORALTABLET
Approved
Dec 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

CLINICAL PHARMACOLOGY Nadolol tablets, USP is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic…

Indications (3)

hypertensionto lower blood pressureheart failure

Clinical Trials (1)

NCT00960245Phase 1Completed

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

Started Jul 1994
34 enrolled
High Blood PressureMigraine HeadachesChest Pain
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers